Meeting
2023 ASCO Annual Meeting
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.
Authors
David Sommerhalder
NEXT Oncology, San Antonio, TX
David Sommerhalder , Erika P. Hamilton , Toru Mukohara , Kan Yonemori , Monica M. Mita , Toshinari Yamashita , Jenny Zheng , LI Liu , Arnab K. Maity , Natasha Homji Mishra , Orlaith Bogg , Meng Li , Patricia LoRusso
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04606446
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1054)
DOI
10.1200/JCO.2023.41.16_suppl.1054
Abstract #
1054
Poster Bd #
275
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
First Author: Patricia LoRusso
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2019 ASCO Annual Meeting
A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
First Author: Melissa Lynne Johnson
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan